Judge approves settlement of more than $500M from Philips recall By Elise Reuter • April 25, 2024 Philips restricted from selling respiratory machines in DOJ consent decree By Elise Reuter • April 9, 2024 Tracking Philips Respironics recalls By Elise Reuter • Updated May 30, 2024 pu...
The companyfirst announced the problemin mid-2021, but efforts to repair or replace the machines have dragged on for years, frustrating patients in the U.S. and other countries. The Dutch company said it has agreed to a consent decree with the Food and Drug Administration and the Department...
Most know Phillips Respironics for theirCPAP sleep apnea machinesand other breathing devices and ventilators. The company has had a challenging last few years after a massive recall of its popular sleep apnea machine andreaching a consent decreewith the Food and Drug Administration. ...
06 May 2024 // GLOBENEWSWIRE Nicklaus, Philips Enhance Patient, Staff Experience, Outcomes For Children 30 Apr 2024 // GLOBENEWSWIRE Philips Q1 Aligned with 2024 Plan, Resolves US Litigation for $1.1B 29 Apr 2024 // GLOBENEWSWIRE FDA Enters Consent Decree Against Philips Respironics ...
Create Portfolio Portfolio Health Check Alert Preferences Subscriptions Premium & Pro About Premium Group Subscriptions Alpha Picks About Alpha Picks FREE Newsletters Investing Groups Learn About Investing Groups Most Popular Free Trials Top Rated Dividend Investing Value Investing Options T...
Philips is restricted from selling many sleep and respiratory products in the U.S., per the terms of a consent decree it struck with the Department of Justice and FDA earlier this year. The company previously recalled the BiPAP machines in 2022 because they contained contaminated plastic and in...
“These changes will have no impact on Philips Respironics’ commitment to complying with the consent decree and will ensure it can provide patients with the highest quality products most efficiently and competitively,” Philips said in a statement to thePittsburgh Post-Gazette. ...
advertisement The company first announced the problem in mid-2021, but efforts to repair or replace the machines have dragged on for years, frustrating patients in the U.S. and other countries. The Dutch manufacturing giant said it has agreed to a consent decree with the Food and Drug Adminis...
MORE ON THIS TOPIC Layoffs Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs December 19, 2024 · 1 min read · Annalee Armstrong Manufacturing Novo Deepens Denmark Commitment With $1.2B Rare Disease Production Facility
December 23, 2024 · 207 min read · BioSpace Editorial Staff Drug shortages FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period December 19, 2024 · 3 min read · Tristan Manalac Layoffs Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs...